(Refiled to remove extraneous text characters in headline)
May 11 (Reuters) - U.S. medical firm Allergan Inc declined to comment on Sunday on a report that it has beenseeking offers from rival companies to combat ValeantPharmaceuticals International's $47 billion cash andshare offer.
A spokeswoman for Allergan told Reuters on Sunday thecompany had no comment to make on whether it was seeking offersfrom other companies, following a report by Bloomberg thatAllergan has so far been rebuffed by rival companies it hastried to interest in making an offer.
Allergan contacted both Sanofi SA and Johnson &Johnson after Valeant made its offer on April 22,Bloomberg said, as well as GlaxoSmithKline Plc andNovartis AG. (Reporting by Scott DiSavino; Editing by Greg Mahlich)
Glaxosmithkline (GSK)